Effects on Serum Uric Acid by Difference of the Renal Protective Effects with Atorvastatin and Rosuvastatin in Chronic Kidney Disease Patients

Abstract

Hyperuricemia and hyperlipidemia have attracted attention as progression factors for chronic kidney disease (CKD). In the drug treatment of hyperuricemia and hyperlipidemia complications, Atorvastatin (ATV), which inhibits urinary protein, increases glomerular filtration rate (GFR) and has renal protective effects, and Rosuvastatin (ROS) were found be suitable because they promote serum uric acid (SUA) excretion. However, these drugs were administered at very high doses in previous studies. In this study, we have investigated the effects of ATV or ROS on renal protective effects and their SUA levels before and three months after each drug administration in CKD patients. We retrospectively investigated outpatients presenting with CKD (stages 3) on the basis of their electronic medical records as subjects. Estimated GFR (eGFR) was significantly increased after ATV administration, whereas no change in eGFR was observed following ROS administration. Furthermore, SUA levels significantly decreased after ATV administration, whereas no changes were observed following ROS administration. Therefore, it may be not necessary to administer drugs that lower the SUA levels to patients presenting with hyperuricemia and hyperlipidemia complications associated with moderate renal failure, such as patients with at least stage 3 CKD. We consider that, by selecting ATV, the renal protective effects and SUA-lowering effect would be sufficient.

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes

“…One retrospective study demonstrated a greater decrease in serum uric acid levels with atorvastatin treatment than with rosuvastatin treatment, which could lead to increased endothelial function and renal blood flow [31]. Even though we did not observe a significant difference between the serum uric acid levels in the two statin treatment groups in the current study, both statin treatments did reduce patient serum uric acid levels.…”

Atorvastatin and trans-caryophyllene for the prevention of leukopenia in an experimental chemotherapy model in Wistar rats

“…Atorvastatin, initially used as a modulator of hypercholesterolemia, has been recently associated with different functions, such as protection against microvascular damage, antifibrotic and anticalcifying effects; in addition, it exhibits antioxidant properties if administered in high doses for the pretreatment of lesions of the myocardium in heart failure, renal disease and abdominal surgery (35)(36)(37). These functions are due to the effect of this drug on populations of mononuclear cells, for example the subpopulations of TCD4 + lymphocytes in reciprocity with or independent from the population of cells of the mononuclear system, such as tissue macrophages, Kupffer cells in the liver, microglial cells in the central nervous system and mucosal dendritic cells (38)(39)(40).…”

Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis

“…For instance, rosuvastatin could reduce the levels of Ox-LDL in the plasma of hemodialysis patients with end-stage renal disease (7). Rosuvastatin could control the progress of liver fibrosis by inhibiting the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), which is a key enzyme in the accumulation of cholesterol (8).…”